Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution
Launched by INSTITUTO DE INVESTIGACIÓN SANITARIA DE LA FUNDACIÓN JIMÉNEZ DÍAZ · Feb 19, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called ursodeoxycholic acid on gallbladder polyps, which are small growths in the gallbladder. The main goal is to find out if this treatment can help reduce the size of these polyps, potentially avoiding the need for more frequent check-ups or even surgery. The trial involves patients who have gallbladder polyps but are not candidates for surgery or have chosen not to have surgery. Participants will take ursodeoxycholic acid for at least six months as part of their usual care.
To be eligible for this study, participants should have gallbladder polyps that are less than 5 mm in size and meet specific health criteria, such as being over 60 years old or having other risk factors. Those who have already taken lower doses of this medication won’t be included. Throughout the trial, researchers will compare the changes in polyp size between those who receive the medication and those who do not, helping to understand if the treatment is effective. If you or a family member are considering this trial, it could offer valuable insights into managing gallbladder polyps.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with gallbladder polyps eligible for standard follow up (without indication for cholecystectomy or patient decline surgery or polyps \< 5mm without risk factors such as age\>60 years, primary sclerosing cholangitis, asian ethnicity, sessile polypoid lesion)
- Exclusion Criteria:
- • Patients with gallbladder polyps that received ursodeoxycolic acid doses lower than 10mg/kg/day
About Instituto De Investigación Sanitaria De La Fundación Jiménez Díaz
The Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (IIS-FJD) is a leading biomedical research institute based in Madrid, Spain, dedicated to advancing healthcare through innovative research and clinical trials. Affiliated with the Fundación Jiménez Díaz Hospital, IIS-FJD focuses on translating scientific discoveries into effective treatments and therapies, fostering collaboration among researchers, healthcare professionals, and academic institutions. With a commitment to improving patient outcomes, the institute emphasizes interdisciplinary approaches in areas such as oncology, cardiovascular health, and rare diseases, making significant contributions to the field of medical research and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Collado Villalba, Madrid, Spain
Patients applied
Trial Officials
Tihomir Georgiev, MD, PhD
Principal Investigator
Hospital Universitario General de Villalba, Madrid, Spain
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported